Navigation Links
Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc.
Date:1/15/2014

LAVAL, Quebec, Jan. 15, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced that the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") with respect to the previously announced tender offer by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), for all of the outstanding shares of common stock of Solta Medical, Inc. (NASDAQ: SLTM) ("Solta") at a price of $2.92 per share, net to the seller in cash, without interest (less any required withholding taxes) and subsequent merger of Purchaser with Solta expired at 11:59 p.m., New York City time on January 14, 2014.  The expiration of the HSR waiting period satisfies one of the conditions to consummate the tender offer.

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology, and branded generics.  More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

Forward-Looking Statements

This press release may contain forward-looking statements regarding, among other things, the proposed acquisition by Valeant of Solta and expected timing of the transaction.  Because these statements reflect Valeant's current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties.  Investors should note that many factors could affect the proposed business combination of the
'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Presentation Schedules, Stock Movements, Agreements, and New Appointments - Research Report on Celgene, Merck, Bristol-Myers, Valeant, and Mylan
2. Valeant Pharmaceuticals To Present At Industry Conferences
3. Valeant Pharmaceuticals Agrees to Acquire Solta Medical for $2.92 Per Share in Cash
4. Valeant Pharmaceuticals Announces Redemption Of The Remaining $465.5 Million Aggrerate Principal Amount Of Its Outstanding 6.50% Senior Notes Due 2016
5. Valeant Pharmaceuticals Announces Pricing Of Private Offering Of Senior Notes
6. Valeant Pharmaceuticals Announced Redemption Of $450 Million Aggregate Principal Amount Of Its Outstanding 6.50% Senior Notes Due 2016
7. Valeant Pharmaceuticals Reports 2013 Third Quarter Financial Results
8. Valeant Pharmaceuticals Announces Settlement Agreement With Anacor
9. Valeant Pharmaceuticals Announces Partnership With National Coalition Against Domestic Violence
10. Valeant Pharmaceuticals Announces Continuance
11. Valeant Pharmaceuticals Reports 2013 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... FRANCISCO , July 29, 2015  Nektar Therapeutics (Nasdaq: ... second quarter ended June 30, 2015 on Wednesday, August 5, ... Robin , president and chief executive officer, will host a ... Eastern Time (ET)/2:00 p.m. Pacific Time (PT). ... conference call can be accessed through a link that is ...
(Date:7/29/2015)... 29, 2015 Unilife Corporation (NASDAQ: ... and supplier of injectable drug delivery systems, today ... instant patch pumps for insulin. ... pump that does not require filling or assembly ... pre-assembled like an insulin pen, only three intuitive ...
(Date:7/29/2015)... 2015  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ... second quarter ended June 30, 2015. "We ... and Fanapt" said Mihael H. Polymeropoulos M.D., Vanda,s President ... cycle management of our products set the stage for ... Financial Highlights , Total net product sales ...
Breaking Medicine Technology:Nektar to Announce Financial Results for the Second Quarter 2015 on Wednesday, August 5, 2015, After Close of U.S.-Based Financial Markets 2Nektar to Announce Financial Results for the Second Quarter 2015 on Wednesday, August 5, 2015, After Close of U.S.-Based Financial Markets 3Unilife Introduces World's First Instant Patch Pump for Insulin 2Unilife Introduces World's First Instant Patch Pump for Insulin 3Unilife Introduces World's First Instant Patch Pump for Insulin 4Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 2Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 3Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 4Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 5Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 6Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 7Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 8Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 9Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 10Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 11Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 12Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 13Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results 14
... 2011 Eli Lilly and Company (NYSE: ... signed agreements with private investors Care Capital and ... and privately-held biotechnology company. BioCritica, based in Central ... development and commercialization of Xigris® (drotrecogin alfa (activated)), ...
... ATLANTA, May 23, 2011 CardioMEMS, Inc ., ... is commercializing a proprietary wireless sensing and communication technology ... and CEO, Jay Yadav, M.D., was presented with a ... by the Atlanta Business Chronicle.  The award was conferred ...
Cached Medicine Technology:Lilly and Investor Group Form New Critical Care Company BioCritica, Sign Xigris License Agreement 2Lilly and Investor Group Form New Critical Care Company BioCritica, Sign Xigris License Agreement 3Lilly and Investor Group Form New Critical Care Company BioCritica, Sign Xigris License Agreement 4Lilly and Investor Group Form New Critical Care Company BioCritica, Sign Xigris License Agreement 5Lilly and Investor Group Form New Critical Care Company BioCritica, Sign Xigris License Agreement 6Lilly and Investor Group Form New Critical Care Company BioCritica, Sign Xigris License Agreement 7CardioMEMS Founder Dr. Jay Yadav Honored With Health-Care Heroes Award by the Atlanta Business Chronicle 2CardioMEMS Founder Dr. Jay Yadav Honored With Health-Care Heroes Award by the Atlanta Business Chronicle 3
(Date:7/30/2015)... Washington, DC (PRWEB) , ... July 30, 2015 ... ... top global managers at multinational organizations and NGO’s, according to a new survey ... today, also shows that property damage and employee medical expenses represented the largest ...
(Date:7/30/2015)... ... , ... HEALTHCAREfirst , the leading provider of cloud-based software, services and ... a free webinar detailing the 2016 proposed rule from CMS for home health. , ... of Regulatory Affairs for the National Association for Home Care and Hospice (NAHC), and ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... and packaging services for consumer brands, recently completed a consolidation of all of ... Previously, the company operated out of two separate locations situated 11 miles apart. ...
(Date:7/29/2015)... ... 30, 2015 , ... Macro Wealth Management (MWM) Presidents have increased ... Lifetime program by encouraging their clients to donate their MWM planning fees to the ... McClellan and Tim Streid, who see charitable giving as an important part of financial ...
(Date:7/29/2015)... , ... July 29, 2015 , ... According to data ... Medicare Part D premium is expected to remain stable at $32.50, a figure far ... popular Part D program continues to be a bright spot in American health care. ...
Breaking Medicine News(10 mins):Health News:New Clements Worldwide Global Risk Survey Shows Political Risk and Instability Top Managers' Concerns 2Health News:New Clements Worldwide Global Risk Survey Shows Political Risk and Instability Top Managers' Concerns 3Health News:HEALTHCAREfirst Announces Home Health Industry Regulatory Review Webinar 2Health News:Case Mason Consolidates Operations to Larger Facility for Increased Efficiency, Improved Service 2Health News:Case Mason Consolidates Operations to Larger Facility for Increased Efficiency, Improved Service 3Health News:Smile for a Lifetime (S4L) Partners with Macro Wealth Management (MWM) Helping More Children Get Braces 2
... K. Bickel, director of the Center for Substance Abuse ... selected as the 2011 recipient of the American Psychological ... Association for Behavior Analysis International, the award recognizes individuals ... to awards chair Cythia Pietras, the award is being ...
... patients participate in clinical trials in part due to a ... published Feb. 11 in The Journal of the National ... trials are accepting participants, according to the National Cancer Institute ... participate in them. Prior studies suggest that most eligible patients ...
... News) -- When someone is trying to fake remorse, ... from one emotion to another very quickly, and speak ... could prove valuable to judges and parole board members, ... and parole release decisions, according to the study authors. ...
... DALLAS Feb. 14, 2011 UT Southwestern ... technology to diagnose Alzheimer,s disease from blood samples ... technology, which uses synthetic molecules to seek out ... eventually in the development of specific biomarkers for ...
... Dennis Thompson HealthDay Reporter , FRIDAY, Feb. 11(HealthDay ... carrying around the raw materials to save at least one ... blood, bone marrow and even the stem cells contained in ... people afflicted with terrible diseases, health officials say. But ...
... disease with a naturally present brain chemical signal ... mechanisms of the disease and open a future ... the University of South Florida Department Neurosurgery and ... Administration Hospital, Tampa. Their findings are published ...
Cached Medicine News:Health News:Brain researcher recognized for contributions to understanding, treatment of drug dependence 2Health News:Few physicians refer patients to cancer clinical trials 2Health News:Few physicians refer patients to cancer clinical trials 3Health News:Clues May Reveal When a Person Is Faking Remorse 2Health News:Preliminary new blood test to detect Alzheimer's disease uncovered 2Health News:Need for Blood and Organ Donors Continues to Grow 2Health News:Need for Blood and Organ Donors Continues to Grow 3Health News:Need for Blood and Organ Donors Continues to Grow 4Health News:Need for Blood and Organ Donors Continues to Grow 5Health News:Naturally occurring brain signaling chemical may be useful in understanding Parkinson's 2
... Our breadth of infectious disease ELISA products ... With standard assay protocols for faster integration ... ELISA products provide increased reliability and run-to-run ... antibody detection assays for a wide range ...
... ELISA test for Clostridium difficile antigen that ... sensitivity. That means the laboratory can quickly, ... negatives - which can represent up to ... the organism - and be sure that ...
... Difficile Tox A/B II is a second-generation rapid ... A and B in fecal specimens. The test ... results detecting not only the more common toxin ... A-/B+. It's easy to perform, produces no indeterminates ...
... now offers the first and only ... and monitoring of bladder cancer patients. ... quantitative microplate enzyme immunoassay that detects ... the urine of patients with bladder ...
Medicine Products: